MediPharm Labs has received a Cannabis Drug Licence (“CDL licence”) from Health Canada.
"The CDL licence is a critical licence required in the qualification for MediPharm Labs to manufacture and supply drugs that contain cannabis," MediPharm team explains. "These products include pharmaceutical prescription drugs that have been classified as drugs with a Drug Identification Number (DIN)."
“With a growing interest in pharmaceutical products containing cannabis and thousands of active trials occurring globally, MediPharm has positioned itself as an essential part of the pharmaceutical industry supply chain,” said Keith Strachan, President and Interim CEO, MediPharm Labs. “The groundwork required for a CDL licence began many years ago as we embarked on our journey to become a GMP certified platform. This CDL licence enhances our opportunity and with our existing pharma customers, while also opening the door to working with additional large and smaller pharma companies, to produce existing approved cannabis drugs or develop and manufacture new and innovative drugs through later stage clinical trials.”
"MediPharm is positioned to supply cannabis based pharmaceutical drugs and active pharmaceutical ingredients to other CDL licence holders and clinical research trials for novel drug discovery."
For more information:
MediPharm Labs
151 John Street, Barrie
+1 705 719 7425
medipharmlabs.com